A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Theriau, Christopher F.
Feng, Jamie
Eng, Lawson
Shepherd, Frances A.
DeCarolis, Mary
Glenns, Vivian
Kulkarni, Swati
VanderMeer, Rachel
Zurawska-Fortin, Urszula
Hao, Desiree
Le, Lisa
Wozniczka, Isabel
Al-Kindy, Aida
Xie, Danny
Zhang, Tong
Subramanian, Vasanth
Stockley, Tracy
Bradbury, Penelope A.
Liu, Geoffrey
Leighl, Natasha B.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT206
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [23] Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Piperdi, Bilal
    Bradley, Kendra J.
    Bathini, Venu
    Zekos, Colleens M.
    Hanrahan-Boshes, Meredith
    Walsh, William V.
    CANCER RESEARCH, 2010, 70
  • [24] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Phase I/II study of gefitinib in combination with vorinostat in patients with advanced non-small cell lung cancer (NSCLC) who progressed on prior chemotherapy
    Han, Ji-Youn
    Lee, Soo Hyun
    Yun, Tak
    Lee, Young Jooo
    Hwang, Kum Hui
    Ryu, Sunah
    Kim, Heung Tae
    Lee, Jin Soo
    CANCER RESEARCH, 2014, 74 (19)
  • [26] A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Ukena, D
    Berg, M
    Leutz, M
    Zell, L
    Schlimmer, P
    Sybrecht, GW
    LUNG CANCER, 1998, 19 (01) : 31 - 36
  • [27] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
  • [28] PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC)
    Kordbacheh, T.
    Chan, C.
    Bossons, A.
    Franks, K.
    McDonald, F.
    Forster, M.
    Mendes, R.
    Quezada, S.
    Dovedi, S.
    Ralph, C.
    Popat, S.
    Harrington, K.
    Melcher, A.
    Popple, A.
    Illidge, T.
    Faivre-Finn, C.
    LUNG CANCER, 2017, 103 : S75 - S76
  • [29] Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).
    Kawabata, S
    Oka, M
    Fukuda, M
    Kinoshita, A
    Fukuda, M
    Nagashima, S
    Nakamura, Y
    Nakano, H
    Soda, H
    Kohno, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S
  • [30] A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
    Koh, R. Keng
    Califano, R.
    Dean, E.
    Kosmin, J.
    Ataman, O.
    Jackson, A.
    Blackhall, F. H.
    Faivre-Finn, C.
    LUNG CANCER, 2010, 67 : S33 - S34
12345